Search
-
New research suggests that concerns about threats to democracy match the economy and immigration as issues shaping the 2024 election
Ipsos poll finds that negative partisanship is the main issue concern for two in five Americans
-
Americans split on continuing military aid to Israel
Meanwhile, Reuters/Ipsos polling finds a plurality say they trust neither Biden nor Trump to broker peace in the Middle East
-
February 2024 Reuters/Ipsos Core Political
Findings of the February 2024 Reuters/Ipsos Core Political
-
Majority of Americans oppose Alabama Supreme Court ruling around IVF
New Axios/Ipsos poll shows fewer than half are familiar with the ruling, but those who are aware stand in strong opposition
-
Hybrid work (and commuting) really seem here to stay
The number of employees who say their employers have set hybrid work guidelines has increased 9 percentage points in the last year, according to new data from the Ipsos Consumer Tracker.
-
A question of gender
Read more about the importance of asking about gender in an inclusive way, especially when conducting international research.
-
It's a major global election year, and populism is on the ballot
Below are five charts on where the world stands on populism and where things could head in 2024
-
ESG: A hidden driver for brand success in healthcare
Read how life sciences companies can go beyond the organizational level and apply their ESG strategy to individual brands, and how doing so with authenticity can serve as an additional factor driving brand success.
-
Half of Americans say they have been in a 10+ year age-gap relationship
New Ipsos poll finds that about seven in ten Americans rate sexual satisfaction and fun aspects higher in those relationships who have 10+ years of age difference
-
Understanding Patients with Metastatic Breast Cancer – A Preference for Oral Treatments
Research conducted by Ipsos in collaboration with Living Beyond Breast Cancer and funded by Eli Lilly and Company explores the time commitment and treatment preferences among women living with ER+, HER2- metastatic breast cancer